Wells Fargo & Company Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet (NYSE:ZBH) had its price target boosted by stock analysts at Wells Fargo & Company from $93.00 to $98.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 5.32% from the company’s previous close.

ZBH has been the topic of several other reports. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a report on Friday, January 9th. Barclays lowered their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 5th. Stifel Nicolaus set a $110.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. Finally, BTIG Research reissued a “buy” rating and set a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $106.10.

Zimmer Biomet Stock Up 1.8%

ZBH stock traded up $1.65 during midday trading on Wednesday, hitting $93.05. The company’s stock had a trading volume of 272,704 shares, compared to its average volume of 2,292,380. The company’s fifty day moving average price is $89.97 and its 200 day moving average price is $95.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. Zimmer Biomet has a twelve month low of $84.59 and a twelve month high of $114.44. The stock has a market capitalization of $18.44 billion, a P/E ratio of 23.02, a PEG ratio of 2.29 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts predict that Zimmer Biomet will post 8.22 EPS for the current year.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Zimmer Biomet by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after acquiring an additional 192,517 shares in the last quarter. Dodge & Cox grew its position in shares of Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after purchasing an additional 1,118,710 shares in the last quarter. Capital International Investors increased its holdings in shares of Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after purchasing an additional 778,467 shares during the period. American Century Companies Inc. raised its position in shares of Zimmer Biomet by 8.7% in the second quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after buying an additional 458,903 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Zimmer Biomet by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after buying an additional 36,611 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat — EPS $2.42 vs $2.38 est and revenue $2.24B, up 10.9% YoY, driven by strong hip/knee demand; this is the primary bullish catalyst. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Positive Sentiment: Analyst support — BTIG reaffirmed a Buy with a $112 price target (roughly 22% upside vs. current price), which can lend further confidence to buyers. Benzinga BTIG coverage
• Neutral Sentiment: FY‑2026 guidance set to $8.30–$8.45 EPS and revenue $8.4–$8.6B — roughly in line with consensus on EPS but slightly conservative on revenue, so guidance is more measured than bullish. Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance
• Negative Sentiment: Margin contraction noted in the quarter — operating/margin pressure (partly from costs and tariffs) reduces near-term earnings leverage and explains management’s conservative tone. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
• Negative Sentiment: Analyst caution — Needham reaffirmed a Hold, and management flagged tariff and margin headwinds that could limit upside until FCF/margin trends improve. Benzinga Needham coverage

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.